These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34781168)

  • 1. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Vicier C; Sfumato P; Isambert N; Dalenc F; Robert M; Levy C; Rezai K; Provansal M; Adélaïde J; Garnier S; Guille A; Carbuccia N; Popovici C; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Pakradouni J; Bertucci F; Boher JM; Sabatier R; Gonçalves A
    Eur J Cancer; 2021 Dec; 159():205-214. PubMed ID: 34781168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
    Sabatier R; Vicier C; Garnier S; Guille A; Carbuccia N; Isambert N; Dalenc F; Robert M; Levy C; Pakradouni J; Adelaïde J; Chaffanet M; Sfumato P; Mamessier E; Bertucci F; Goncalves A
    Mol Oncol; 2022 May; 16(10):2057-2070. PubMed ID: 35122700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
    Azaro A; Rodon J; Calles A; Braña I; Hidalgo M; Lopez-Casas PP; Munoz M; Westwood P; Miller J; Moser BA; Ohnmacht U; Bumgardner W; Benhadji KA; Calvo E
    Invest New Drugs; 2015 Jun; 33(3):710-9. PubMed ID: 25902900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
    Lynce F; Williams JT; Regan MM; Bunnell CA; Freedman RA; Tolaney SM; Chen WY; Mayer EL; Partridge AH; Winer EP; Overmoyer B
    Cancer Chemother Pharmacol; 2021 May; 87(5):673-679. PubMed ID: 33585999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
    Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
    J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
    Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
    Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Ocana A; Gil-Martin M; Antolín S; Atienza M; Montaño Á; Ribelles N; Urruticoechea A; Falcón A; Pernas S; Orlando J; Montero JC; Escudero MJ; Benito S; Caballero R; Carrasco E; Rojo F; Pandiella A; Ruiz-Borrego M
    Breast Cancer Res Treat; 2019 Apr; 174(3):693-701. PubMed ID: 30607629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
    Hurvitz SA; Dalenc F; Campone M; O'Regan RM; Tjan-Heijnen VC; Gligorov J; Llombart A; Jhangiani H; Mirshahidi HR; Tan-Chiu E; Miao S; El-Hashimy M; Lincy J; Taran T; Soria JC; Sahmoud T; André F
    Breast Cancer Res Treat; 2013 Oct; 141(3):437-46. PubMed ID: 24101324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
    Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
    Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
    Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
    Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.